News

Business Wire2y
New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB ...
Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncol . 2019;15(11):1207-1217. doi ...
Business Wire1y
DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with ... - Business Wire
Castle announced a new study demonstrating DecisionDx®-Melanoma outperforms the MSKCC nomogram in identifying patients at low risk of SLN positivity.